Texas
LATEST FROM BIOSPACE
In light of the Thanksgiving season, here are six things about biopharma that we are thankful for.
With the Thanksgiving holiday fast-approaching in the United States, some investors are giving their thanks to five different pharma companies that became available on the stock exchange this month with an initial public offering.
Some analysts are checking their crystal balls to get an idea if 2020 will be a busy year for investors. The early thinking on biotech is yes.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
FUJIFILM Corporation will invest 13 billion yen (about $120 million) to expand the company’s gene therapy business and establish a new Gene Therapy Innovation Center adjacent to its current facility in College Station, Texas and add about 100 jobs.
Bardoxolone methyl is an experimental, oral, once-a-day activator of Nrf2, a transcription factor that induces molecular pathways involved in resolving inflammation.
Medical and health service managers work hard to improve the quality and efficiency required to deliver first rate healthcare services.
Could an immunosuppressant boost cognition in senior citizens? A recent animal study from the University of Texas Health Science Center at San Antonio suggests the possibility.
Under the new deal, Artios Pharma licensed rights to research, develop, manufacture and commercialize products globally from a small-molecule ATR inhibitor program that was jointly developed by MD Anderson and ShangPharma.
They announced an exclusive license deal and research agreement to develop cord-blood derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies.
PRESS RELEASES